Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/71161
Title:
Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma.
Authors:
Silva, Priyamal; West, Catharine M L; Slevin, Nicholas J ( 0000-0002-3367-7013 ) ; Valentine, Helen R; Ryder, W David J; Hampson, Lynne; Bibi, Rufzan; Sloan, Philip; Thakker, Nalin; Homer, Jarrod J; Hampson, Ian N
Abstract:
PURPOSE: Vaults are multi-subunit structures that may be involved in nucleo-cytoplasmic transport, with the major vault protein (MVP or lung resistance-related protein [LRP]) being the main component. The MVP gene is located on chromosome 16 close to the multidrug resistance-associated protein and protein kinase c-beta genes. The role of MVP in cancer drug resistance has been demonstrated in various cell lines as well as in ovarian carcinomas and acute myeloid leukemia, but nothing is known about its possible role in radiation resistance. Our aim was to examine this in head-and-neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Archived biopsy material was obtained for 78 patients with squamous cell carcinoma of the oropharynx who received primary radiotherapy with curative intent. Immunohistochemistry was used to detect MVP expression. Locoregional failure and cancer-specific survival were estimated using cumulative incidence and Cox multivariate analyses. RESULTS: In a univariate and multivariate analysis, MVP expression was strongly associated with both locoregional failure and cancer-specific survival. After adjustment for disease site, stage, grade, anemia, smoking, alcohol, gender, and age, the estimated hazard ratio for high MVP (2/3) compared with low (0/1) was 4.98 (95% confidence interval, 2.17-11.42; p = 0.0002) for locoregional failure and 4.28 (95% confidence interval, 1.85-9.95; p = 0.001) for cancer-specific mortality. CONCLUSION: These data are the first to show that MVP may be a useful prognostic marker associated with radiotherapy resistance in a subgroup of patients with HNSCC.
Affiliation:
Department of Academic Radiation Oncology, The University of Manchester, Manchester, United Kingdom.
Citation:
Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. 2007, 69 (1):133-40 Int. J. Radiat. Oncol. Biol. Phys.
Journal:
International Journal of Radiation Oncology, Biology, Physics
Issue Date:
1-Sep-2007
URI:
http://hdl.handle.net/10541/71161
DOI:
10.1016/j.ijrobp.2007.02.025
PubMed ID:
17459603
Type:
Article
Language:
en
ISSN:
0360-3016
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSilva, Priyamal-
dc.contributor.authorWest, Catharine M L-
dc.contributor.authorSlevin, Nicholas J-
dc.contributor.authorValentine, Helen R-
dc.contributor.authorRyder, W David J-
dc.contributor.authorHampson, Lynne-
dc.contributor.authorBibi, Rufzan-
dc.contributor.authorSloan, Philip-
dc.contributor.authorThakker, Nalin-
dc.contributor.authorHomer, Jarrod J-
dc.contributor.authorHampson, Ian N-
dc.date.accessioned2009-06-22T13:42:49Z-
dc.date.available2009-06-22T13:42:49Z-
dc.date.issued2007-09-01-
dc.identifier.citationTumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. 2007, 69 (1):133-40 Int. J. Radiat. Oncol. Biol. Phys.en
dc.identifier.issn0360-3016-
dc.identifier.pmid17459603-
dc.identifier.doi10.1016/j.ijrobp.2007.02.025-
dc.identifier.urihttp://hdl.handle.net/10541/71161-
dc.description.abstractPURPOSE: Vaults are multi-subunit structures that may be involved in nucleo-cytoplasmic transport, with the major vault protein (MVP or lung resistance-related protein [LRP]) being the main component. The MVP gene is located on chromosome 16 close to the multidrug resistance-associated protein and protein kinase c-beta genes. The role of MVP in cancer drug resistance has been demonstrated in various cell lines as well as in ovarian carcinomas and acute myeloid leukemia, but nothing is known about its possible role in radiation resistance. Our aim was to examine this in head-and-neck squamous cell carcinoma (HNSCC). METHODS AND MATERIALS: Archived biopsy material was obtained for 78 patients with squamous cell carcinoma of the oropharynx who received primary radiotherapy with curative intent. Immunohistochemistry was used to detect MVP expression. Locoregional failure and cancer-specific survival were estimated using cumulative incidence and Cox multivariate analyses. RESULTS: In a univariate and multivariate analysis, MVP expression was strongly associated with both locoregional failure and cancer-specific survival. After adjustment for disease site, stage, grade, anemia, smoking, alcohol, gender, and age, the estimated hazard ratio for high MVP (2/3) compared with low (0/1) was 4.98 (95% confidence interval, 2.17-11.42; p = 0.0002) for locoregional failure and 4.28 (95% confidence interval, 1.85-9.95; p = 0.001) for cancer-specific mortality. CONCLUSION: These data are the first to show that MVP may be a useful prognostic marker associated with radiotherapy resistance in a subgroup of patients with HNSCC.en
dc.language.isoenen
dc.subjectCancer Proteinsen
dc.subjectOropharyngeal Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAnalysis of Variance-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMultidrug Resistance-Associated Proteins-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshOropharyngeal Neoplasms-
dc.subject.meshPrognosis-
dc.subject.meshRadiation Tolerance-
dc.subject.meshRetrospective Studies-
dc.subject.meshTreatment Failure-
dc.subject.meshVault Ribonucleoprotein Particles-
dc.titleTumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Academic Radiation Oncology, The University of Manchester, Manchester, United Kingdom.en
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.